RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC

NCT05733611 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

5

Enrollment

INDUSTRY

Sponsor class

Stopped Business reasons.

Conditions

Refractory Metastatic Colorectal Cancer
pMMR
MSS

Interventions

BIOLOGICAL: RP2
BIOLOGICAL: RP3
BIOLOGICAL: atezolizumab
BIOLOGICAL: bevacizumab

Sponsor

Replimune, Inc.

Collaborators

[object Object]